膀胱癌保膀胱治疗的免疫联合策略研究进展

打开文本图片集

ABSTRACT：Bladder-preserving treatment has becomearesearch focus due to its potential tobalance therapeutic eficacyand qualityoflife.Inrecent years，therapid development of immunotherapy has brought new opportunities for bladder-sparing strategies.Inhigh-risknon-muscle invasive bladdercancer（HR-NMIBC），emergingregimenssuchasbaciluscalmete-guerinbased immunoenhancement，immuno-chemotherapycombinations，targeted therapy，andgene therapy have demonstrated encouraging eficacy and safety in trials like GU-123 and TRUCE-O2，with complete remission rate ranging from 42%-100% ： In muscle-invasive bladdercancer（MIBC），immunotherapy isbeing integrated with trimodal therapy，radiotherapy， chemotherapy，and antibody-drug conjugates，as evidenced by studies such as ReBirthand BTCRC-GU15-023，which reported significant improvements inbladder-intactevent-freesurvival，progresion-free survival，andcompleteremissionrateTis review summarizes the latest advances in immunotherapy-based bladder-preserving strategies forboth HR-NMIBC and MIBC， aiming to provide insights for future individualized treatment approaches.

KEY WORDS：bladdercancer;muscle-invasive bladder cancer;high-risk non-muscle invasive bladder cancer;immunotherapy; bladder-preserving;trimodal therapy;bacillus calmette-guérin

摘要：保膀胱综合治疗因可以兼顾膀胱癌患者的疗效与生活质量而成为研究热点。（剩余13970字）